We thank the authors who contributed these high interest articles, and all other authors who have contributed articles to CNS Drugs over the course of 2016. The skill and dedication of all authors are critical to the continued publication of the journal.
Mid-2016 saw the release of the ISI Journal Citation Reports and the latest journal impact factors. The impact factor for CNS Drugs held steady, at 4.910, and the journal remains in the top 20% of its respective categories (Pharmacology and Pharmacy, Clinical Neurology, and Psychiatry). The majority of our other journals saw a rise in impact factor against the previous year. Most notably, five of our journals saw an increase of over 10% in impact factor-The Patient: PatientCentered Outcomes Research (17.08% increase), Clinical Drug Investigation (15.99%), the American Journal of Clinical Dermatology (13.17%), Drug Safety (13.52%), and Drugs (12.43%).
Another important milestone was reached for our recently launched open access journals, Drug Safety-Case Reports and Drugs-Real World Outcomes. Content from these journals is now available on PubMed Central. The Adis journals portfolio will expand in 2017, with the launch of PharmacoEconomics-Open. This new journal will be fully open access and will focus on the publication of applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. It joins our other well respected health outcomes publications, PharmacoEconomics, Applied Health Economics and Health Policy, and The Patient: Patient-Centered Outcomes Research.
The quality of published articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for CNS Drugs in the last 12 months:
Marco Mula, UK
